Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma By Ogkologos - January 21, 2025 49 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR Pembrolizumab Combinations Show Promise in mCRPC November 21, 2020 EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... January 21, 2021 Spring Budget 2023: What does it mean for the mission to... March 15, 2023 Load more HOT NEWS As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... EMA Recommends Granting a Marketing Authorisation for Sugemalimab How Becky is helping her children to keep their dad’s memory... Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age
